CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update
Conference call webcast is scheduled for November 22 at 9 a.m. ET.
SINGAPORE, Nov. 17, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology
SINGAPORE, Sept. 25, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency
The MOU signed by CytoMed and Hangzhou CNK Therapeutics Co., Ltd is the first
of several collaborative efforts inNorth Asia.
SINGAPORE, Aug. 15, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited
Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
The Company now has exclusive rights to a US and Chinese patent.
SINGAPORE, Aug. 1, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited
CytoMed Therapeutics to Ring Nasdaq Closing Bell
SINGAPORE, May 11, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited ("CytoMed" or the "Company") (Nasdaq: GDTC), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, will ...
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology
SINGAPORE, May 9, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (Nasdaq: GDTC) ("CytoMed" or the "Company"), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, today ...
CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering
SINGAPORE, April 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited ("CytoMed" or the "Company"), a pre-clinical biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers, today announced ...
